UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

  (Amendment No.    )*

 

 

 

Codiak BioSciences, Inc.

(Name of Issuer)

   

Common Stock par value $0.0001 per share

 

(Title of Class of Securities)

  

192010106

 

(CUSIP Number)

  

December 31, 2020

 

(Date of Event Which Requires Filing of This Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

   Rule 13d-1(b)

☐   Rule 13d-1(c)

☒   Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

 

 
 

CUSIP No.  192010106

13G Page 2 of 16 Pages    

1  

NAMES OF REPORTING PERSON(S)

 

ARCH Venture Fund VIII, L.P.

 

   
2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

 

 

(a)

(b)

3  

SEC USE ONLY

 

 

 

   
4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

  

   
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
 

 5

 

SOLE VOTING POWER

 

0

 

  6  

SHARED VOTING POWER

 

3,854,098

 

  7  

SOLE DISPOSITIVE POWER

 

0

 

  8  

SHARED DISPOSITIVE POWER

 

3,854,098

 

9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

3,854,098

 

   
10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 

   
11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  

20.5%

 

   

 12

 

TYPE OF REPORTING PERSON

   

PN

 

   

 
 

 

CUSIP No.  192010106

13G Page 3 of 16 Pages    

 

1  

NAMES OF REPORTING PERSON(S)

 

ARCH Venture Fund VIII Overage, L.P.

 

   
2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

 

 

(a)

(b)

3  

SEC USE ONLY

 

 

 

   
4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

  

   
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
 

 5

 

SOLE VOTING POWER

 

0

 

  6  

SHARED VOTING POWER

 

3,854,098

 

  7  

SOLE DISPOSITIVE POWER

 

0

 

  8  

SHARED DISPOSITIVE POWER

 

3,854,098

 

9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

3,854,098

 

   
10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 

   
11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  

20.5%

 

   

 12

 

TYPE OF REPORTING PERSON

   

PN

 

   

 
 

CUSIP No.  192010106

13G Page 4 of 16 Pages    

 

1  

NAMES OF REPORTING PERSON(S)

 

ARCH Venture Partners VIII, L.P.

 

   
2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

 

 

(a)

(b)

3  

SEC USE ONLY

 

 

 

   
4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

  

   
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
 

 5

 

SOLE VOTING POWER

 

0

 

  6  

SHARED VOTING POWER

 

3,854,098

 

  7  

SOLE DISPOSITIVE POWER

 

0

 

  8  

SHARED DISPOSITIVE POWER

 

3,854,098

 

9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

3,854,098

 

   
10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 

   
11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  

20.5%

 

   

 12

 

TYPE OF REPORTING PERSON

   

PN

 

   

 
 

CUSIP No.  192010106

13G Page 5 of 16 Pages    

 

1  

NAMES OF REPORTING PERSON(S)

 

ARCH Venture Partners VIII, LLC

 

   
2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

 

 

(a)

(b)

3  

SEC USE ONLY

 

 

 

   
4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

  

   
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
 

 5

 

SOLE VOTING POWER

 

0

 

  6  

SHARED VOTING POWER

 

3,854,098

 

  7  

SOLE DISPOSITIVE POWER

 

0

 

  8  

SHARED DISPOSITIVE POWER

 

3,854,098

 

9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

3,854,098

 

   
10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 

   
11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  

20.5%

 

   

 12

 

TYPE OF REPORTING PERSON

   

OO

 

   

 
 

CUSIP No.  192010106

13G Page 6 of 16 Pages    

 

1  

NAMES OF REPORTING PERSON(S)

 

Keith Crandell

 

   
2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

 

 

(a)

(b)

3  

SEC USE ONLY

 

 

 

   
4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States of America

  

   
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
 

 5

 

SOLE VOTING POWER

 

0

 

  6  

SHARED VOTING POWER

 

3,854,098

 

  7  

SOLE DISPOSITIVE POWER

 

0

 

  8  

SHARED DISPOSITIVE POWER

 

3,854,098

 

9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

3,854,098

 

   
10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 

   
11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  

20.5%

 

   

 12

 

TYPE OF REPORTING PERSON

   

IN

 

   

 
 

CUSIP No.  192010106

13G Page 7 of 16 Pages    

 

1  

NAMES OF REPORTING PERSON(S)

 

Clinton Bybee

 

   
2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

 

 

(a)

(b)

3  

SEC USE ONLY

 

 

 

   
4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States of America

  

   
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
 

 5

 

SOLE VOTING POWER

 

0

 

  6  

SHARED VOTING POWER

 

3,854,098

 

  7  

SOLE DISPOSITIVE POWER

 

0

 

  8  

SHARED DISPOSITIVE POWER

 

3,854,098

 

9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

3,854,098

 

   
10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 

   
11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  

20.5%

 

   

 12

 

TYPE OF REPORTING PERSON

   

IN

 

   

 
 

CUSIP No.  192010106

13G Page 8 of 16 Pages    

 

1  

NAMES OF REPORTING PERSON(S)

 

Robert Nelsen

 

   
2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

 

 

(a)

(b)

3  

SEC USE ONLY

 

 

 

   
4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States of America

  

   
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
 

 5

 

SOLE VOTING POWER

 

0

 

  6  

SHARED VOTING POWER

 

3,854,098

 

  7  

SOLE DISPOSITIVE POWER

 

0

 

  8  

SHARED DISPOSITIVE POWER

 

3,854,098

 

9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

3,854,098

 

   
10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 

   
11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

  

20.5%

 

   

 12

 

TYPE OF REPORTING PERSON

   

IN

 

   

 
 

CUSIP No.  192010106

13G Page 9 of 16 Pages    

 

 

Item 1(a). Name of Issuer:

 

Codiak BioSciences, Inc. (the “Issuer”).

 

 

Item 1(b). Address of Issuer's Principal Executive Offices:

 

35 Cambridge Park Drive, Suite 500, Cambridge, MA 02140.

 

 

Item 2(a). Name of Person Filing:

 

ARCH Venture Fund VIII, L.P. (“ARCH Venture Fund VIII”); ARCH Venture Fund VIII Overage, L.P. (“AVF VIII Overage LP”); ARCH Venture Partners VIII, L.P. (“AVP VIII LP”); ARCH Venture Partners VIII, LLC (“AVP VIII LLC”) (collectively, the “Reporting Entities” and individually, each a “Reporting Entity”); and Keith Crandell (“Crandell”), Robert Nelsen (“Nelsen”) and Clinton Bybee (“Bybee”) (collectively, the “Managing Directors” and individually, each a “Managing Director”). The Reporting Entities and the Managing Directors collectively are referred to as the “Reporting Persons”. The Reporting Persons have entered into a Joint Filing Agreement, dated as of the date hereof, a copy of which is filed with this Schedule 13G as Exhibit 1 (which is incorporated herein by reference), pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k) under the Act. 

 

 

Item 2(b). Address of Principal Business Office or, if none, Residence:

 

8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631.

 

 

Item 2(c). Citizenship:

 

ARCH Venture Fund VIII, AVF VIII Overage LP and AVP VIII LP are limited partnerships organized under the laws of the State of Delaware. AVP VIII LLC is a limited liability company organized under the laws of the State of Delaware. Each Managing Director is a US citizen.

 

 

Item 2(d). Title of Class of Securities.

 

Common stock, par value $0.0001 per share.

 

 

Item 2(e). CUSIP Number.

 

192010106

 

  

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

 

Not Applicable.

 

 
 

CUSIP No.  192010106

13G Page 10 of 16 Pages    

 

Item 4. Ownership:

 

(a)

Amount beneficially owned:

 

ARCH Venture Fund VIII is the record owner of 2,503,903 shares of Common Stock (the “ARCH VIII Shares”) as of December 31, 2020. AVP VIII LP, as the sole general partner of ARCH Venture Fund VIII, may be deemed to beneficially own the ARCH VIII Shares. AVF VIII Overage LP is the record owner of 1,350,195 shares of Common Stock (the “Overage Shares”; combined with ARCH VIII Shares, the “Record Shares”) as of December 31, 2020. AVP VIII LLC, as the sole general partner of AVP VIII LP and AVF VIII Overage LP, may be deemed to beneficially own the Record Shares. As managing directors of AVP VIII LLC, each Managing Director may also be deemed to share the power to direct the disposition and vote of the Record Shares.

 

(b)

Percent of class:

 

See line 11 of the cover sheets. The percentages set forth on the cover sheet for each Reporting Person is based upon 18,767,674 shares of common stock outstanding as of November 19, 2020 as reported on the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 19, 2020.

   
(c) Number of shares as to which such person has:

  (i)

Sole power to vote or to direct the vote:

 

See line 5 of the cover sheets.

     
  (ii)

Shared power to vote or to direct the vote:

 

See line 6 of the cover sheets.

     
  (iii)

Sole power to dispose or to direct the disposition:

 

See line 7 of the cover sheets.

     
  (iv)

Shared power to dispose or to direct the disposition:

 

See line 8 of the cover sheets.

     

Each Reporting Person disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record.

 

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

 

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not applicable.

 

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

 

Item 10. Certifications.

 

Not applicable.

  

 
 

CUSIP No.  192010106

13G Page 11 of 16 Pages    

 

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated:    February 4, 2021

ARCH VENTURE FUND VIII, L.P.

 

By:       ARCH Venture Partners VIII, L.P.

its General Partner

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:                    *               

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS VIII, L.P.

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:                           *                    

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS VIII, LLC

 

By:                           *                                

Keith Crandell

Managing Director

 

 

                                  *                                 

Keith Crandell

 

 

                                  *                                 

Robert Nelsen

 

 

                                  *                                 

Clinton Bybee

 

 

 

 

 

 

 

 
 

CUSIP No.  192010106

13G Page 12 of 16 Pages    

 

 

 

 

ARCH VENTURE FUND VIII OVERAGE, L.P.

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:                        *                       

Keith Crandell

Managing Director

 

 

 

 

 

 

 

 

* By:   /s/ Mark McDonnell                  

Mark McDonnell as

Attorney-in-Fact

 

 

This Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as Exhibit 2.0 and Exhibit 2.1 and incorporated herein by reference.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 

CUSIP No.  192010106

13G Page 13 of 16 Pages    

 

 

Exhibit 1

 

AGREEMENT

 

Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Codiak BioSciences, Inc.

 

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

 

 

Dated:    February 4, 2021

ARCH VENTURE FUND VIII, L.P.

 

By:       ARCH Venture Partners VIII, L.P.

its General Partner

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:                    *              

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS VIII, L.P.

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:                        *                       

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS VIII, LLC

 

By:                           *                             

Keith Crandell

Managing Director

 

 

                                  *                                 

Keith Crandell

 

 

                                  *                                 

Robert Nelsen

 

 

                                  *                                 

Clinton Bybee

 

 

 

 

 

 

 

 
 

CUSIP No.  192010106

13G Page 14 of 16 Pages    

 

 

 

 

ARCH VENTURE FUND VIII OVERAGE, L.P.

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:                           *                    

Keith Crandell

Managing Director

 

 

 

 

 

 

 

 

* By:   /s/ Mark McDonnell                  

Mark McDonnell as

Attorney-in-Fact

 

 

This Agreement was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as Exhibit 2.0 and Exhibit 2.1 and incorporated herein by reference.

 

 

 

 

 

 

 

 

 

 

 

 

 
 

CUSIP No.  192010106

13G Page 15 of 16 Pages    

Exhibit 2.0

 

POWERS OF ATTORNEY

 

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark McDonnell his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, member, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney shall remain in full force and effect with respect to each undersigned person unless and until six months after such person is both no longer a Managing Director of ARCH Venture Partners and no longer serving on the board of directors of any portfolio company of any ARCH Venture Partners fund.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 9th day of March, 2015.

 

ARCH VENTURE FUND VIII, L.P.

 

By:       ARCH Venture Partners VIII, L.P.

its General Partner

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:    /s/ Keith Crandell   

Managing Director

 

 

ARCH VENTURE PARTNERS VIII, L.P.

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:   /s/ Keith Crandell                 

Managing Director

 

 

ARCH VENTURE PARTNERS VIII, LLC

 

By:        /s/ Keith Crandell                         

Managing Director

 

 

/s/ Keith Crandell                                       

Keith Crandell

 

 

/s/ Robert Nelsen                                       

Robert Nelsen

 

 

/s/ Clinton Bybee                                       

Clinton Bybee

 

 

/s/ Kristina Burow                                      

Kristina Burow

 

 

/s/ Paul Thurk                                             

Paul Thurk

 

 

 

 

 
 

CUSIP No.  192010106

13G Page 16 of 16 Pages    

Exhibit 2.1

 

 

POWERS OF ATTORNEY

 

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark McDonnell his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, member, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney shall remain in full force and effect with respect to each undersigned person unless and until six months after such person is both no longer a Managing Director of ARCH Venture Partners and no longer serving on the board of directors of any portfolio company of any ARCH Venture Partners fund.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 26th day of July, 2017.

 

 

ARCH VENTURE FUND VIII OVERAGE, L.P.

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:   /s/ Keith Crandell               

Managing Director

 

 

ARCH VENTURE PARTNERS VIII, L.P.

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:   /s/ Keith Crandell               

Managing Director